Formycon AG Launches Subscription for New Corporate Bond

Formycon AG, a biosimilars developer based in Planegg-Martinsried, Germany, has announced the start of the subscription period for its 2025/2029 corporate bond. The Luxembourg financial supervisory authority approved the securities prospectus on June 17, 2025. The bond, targeting a volume of EUR 50 million, offers a variable interest rate linked to the three-month EURIBOR plus a margin of 7.0% to 7.5% annually, with the final margin to be announced on June 30.

The subscription is available via Formycon's website until June 27 and through Deutsche Börse’s DirectPlace from June 20 to June 30. Guided by IKB Deutsche Industriebank AG and Pareto Securities AS, the bond aims to support Formycon's growth strategy by expanding its biosimilar product portfolio.

The four-year bond, not subordinated or secured, will trade on the Frankfurt Stock Exchange and potentially on the Oslo Stock Exchange's Euronext ABM within six months.